GPNMB and breast cancer: There are several examples of practice observations that sustain the use of certain agents in specific clinical settings e.g.: the gene expression profile confirmed the LAR subgroup of TNBC; this particular subgroup could benefit from anti-androgen therapy (bilucamide, enzalutamide) [8]; PDL-1 overexpressed TNBC could benefit pembrolizumab therapy [19], while for the transmembrane glycoprotein NMB (gpNMB)-overexpressed BC glembatumumab vedotin may represent another promising approach [20].